CASE REPORT


https://doi.org/10.5005/jp-journals-10055-0077
AMEI’s Current Trends in Diagnosis and Treatment
Volume 3 | Issue 2 | Year 2019

A Huge Retroperitoneal Liposarcoma: A Case Report


Rajat Sharma1, Mohit Sharma2, Sanchit Bansal3, Karaninder Singh4, Neeti R Singh5

1–5Department of Surgery, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India

Corresponding Author: Mohit Sharma, Department of Surgery, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India, Phone: +91 9814651788, e-mail: drmohit.gis@gmail.com

How to cite this article Sharma R, Sharma M, Bansal S, et al. A Huge Retroperitoneal Liposarcoma: A Case Report. AMEI’s Curr Trends Diagn Treat 2019;3(2):90–92.

Source of support: Dr Mohit Sharma, Associate Professor, Department of Surgery and Dr Richa G Thaman, Professor, Department of Physiology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab, India.

Conflict of interest: None

ABSTRACT

Aim: Retroperitoneal soft-tissue sarcomas are relatively uncommon diseases, and the most frequent histotype, ranging from 20 to 45% of all cases, is represented by liposarcoma, which is a hard-to-treat condition for its local aggressiveness and clinical aspecificity.

Presentation of case: We report a case of a 69-year-old woman who underwent surgical resection for a giant pleomorphic retroperitoneal liposarcoma.

Discussion: Currently, chemotherapy for retroperitoneal soft-tissue sarcomas is not effective, and radiotherapy has limited efficacy due to the toxicity affecting adjacent intra-abdominal structures and showed validity only in case of high-grade malignancy by reducing local recurrence but with no advantage in overall survival. Nowadays, complete surgical resection remains the most important predictor of local recurrence and overall survival.

Conclusion: The removal of a retroperitoneal sarcoma of remarkable size is a challenge for the surgeon owing to the anatomical site, the absence of an anatomically evident vascular-lymphatic peduncle, and the adhesions contracted with the contiguous organs and great vessels. Therefore, we believe that, particularly for large-sized diseases associated with high-grade malignancy, a complete surgical resection with the removal of the contiguous intra- and retroperitoneal organs when infiltrated represents the only therapeutic option to obtain a negative margin and therefore an oncological radicality.

Keywords: Myxoid areas, Radical treatment, Retroperitoneal liposarcoma, Soft-tissue sarcomas.

INTRODUCTION

Among the retroperitoneal sarcomas that represent the 10–15% of all soft-tissue sarcoma, the most common histotype is represented by liposarcoma, which ranges from 20 to 45% of all cases.1,2 It commonly occurs in patients aged 40–60 years old with a 1:1 ratio between male and female. The liposarcoma may have weight and dimension variable: those over 20 kg are called giant liposarcomas and are extremely rare.3 We report a case of liposarcoma even more uncommon for its origin from perirenal fat: in fact approximately 13% are located in the retroperitoneal area and less than 1/3 of these arise from perinephric fat.4

CASE DESCRIPTION

We report the case of a 69-year-old male who was referred to our observation for a progressive volumetric increase of the abdomen.

All relevant investigations were done. Ultrasonography (USG) abdomen demonstrated a large lesion with ill-defined area measuring 20 × 17 × 13 cm in the right lumbar and right iliac region with extension into pelvis, posterior to anterior abdominal wall displacing the bowel loops superiorly and toward left side. Right kidney is displaced posteriorly, suggestive of liposarcoma.

Contrast enhanced computed tomography (CECT) abdomen demonstrated a large well-defined fat density lesion measuring approximately 14 × 13 × 11 cm in the right hypochondrium and lumbar regions, in region of right paracolic gutter, extending superiorly up to inferior surface of liver; medially displacing small bowel loops and mesenteric vessels; and posteriorly compressing upon inferior vena cava (IVC), right iliac vessels, and psoas muscle. It also shows a similar lesion in pelvis measuring 13 × 11 × 10 cm inferiorly compressing the urinary bladder and rectosigmoid. Few small-sized lymph nodes are noted in the mesentery and para-aortic regions as shown in Figure 1.

Fig. 1: Computed tomography scan showing the presence of the bulky lesion stretching from the subhepatic region to the pelvic cavity

Figs 2A to C: (A) Bulky lesion originating from retroperitoneal region; (B) Weight of specimen: The retroperitoneal mass weighs 2.980 kg; (C) Excised surgical specimen

Preoperative assessment was done.

B/L DJ stenting was done to preserve ureters 2 days prior to surgery under spinal anesthesia. The patient was taken up for an explorative laparatomy under general anesthesia (GA) which revealed the presence of a bulky lesion of 2.9 kg originating from the retroperitoneal region as shown in Figure 2, respectively.

The postoperative course was uneventful, and the patient was discharged on the seventh postoperative day. After 3 weeks, DJ stent was removed. The definitive histological diagnosis was liposarcoma—well differentiated, with free resection margin. At 2 months of follow-up, the patient is disease free.

DISCUSSION

The retroperitoneal liposarcomas are generally neoplasms with a low or intermediate grade of malignancy. The occurrence of hematogenous metastasis is a rare finding at the time of diagnosis; the lung represents the main site of distant metastasis. From a histologic point of view, in according to the morphological characteristics and on the strength of cytogenetic aberrations, now widely accepted, we can divide the liposarcoma in 4 types undifferentiated, pleomorphic, well differentiated, myxoid/round cell.5 The undifferentiated and pleomorphic types are neoplasm with high grade of malignancy accompanied by remarkable biological aggressiveness and with metastatic potential, while well-differentiated and myxoid/round cell forms are tumors with a low grade of malignancy, associated with a more favorable prognosis.6

The resection of a retroperitoneal sarcoma of remarkable size is a challenge for the surgeon owing to the anatomical site, absence of an anatomically evident vascular-lymphatic peduncle that makes it hard to obtain a safe margin, and adherences with the contiguous organs and with the great vessels. Therefore, the retroperitoneal liposarcoma shows a high rate of local recurrence after surgical excision. Actually, the overall survival at 5 years for the various histological subtypes, well-differentiated, myxoid/round cell, undifferentiated, and pleomorphic, ranges from 90, 60–90, 75, and 30–50%, respectively.7

Actually, the chemotherapy treatment used in the adjuvant or neoadjuvant setting has no benefit in the clinical course of the disease. Doxorubicin only yields a response rate of 18–29%. The antibiotic salinomycin, a potassium ionophore, appears to increase the chemosensitivity to the doxorubicin; so, it may be used to decrease the doxorubicin dosage and its toxic side effects.8 Neoadjuvant therapy may be taken into account in cases of dedifferentiated liposarcoma, which has an increased risk of recurrence and metastasis. It is necessary for an accurate subtype-specific diagnosis to evaluate the neoadjuvant therapy.

CONCLUSION

Our case shows some peculiar characteristics: first, its origin from perirenal fat, in fact approximately 13% are located in the retroperitoneal area and less than 1/3 of these arise from perinephric fat, and, second, the huge size (20 × 17 × 13 cm) of liposarcoma. Actually, the surgical approach represents the only therapeutic option that can provide a concrete perspective of care considering lack of support of effective complementary therapies. An aggressive surgical attitude that includes extended resections of the extra- and intaperitoneal structures is justified, especially in tumors of large size, to obtain a microscopic radicality of resection margins.

REFERENCES

1. Leao P, Vilaça S, Oliveira M, et al. Giant recurrent retroperitoneal liposarcoma initially presenting as inguinal hernia: review of literature. Int J Surg Case Rep 2012;3(3):103–106. DOI: 10.1016/j.ijscr.2011.03.009.

2. Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228(3):355–365. DOI: 10.1097/00000658-199809000-00008.

3. Hashimoto Y, Hatakeyama S, Tachiwada T. Surgical treatment of a giant liposarcoma in a Japanese man. Adv Urol 2010. DOI: 10.1155/2010/943073.

4. Martínez León MI, Martos Forniels JA, Arranz Salas IM, et al. Liposarcoma of the perirenal cell. Arch Esp Urol 2003;56(9):1050–1054.

5. Crago AM, Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 2011;23(4):373–378. DOI: 10.1097/CCO.0b013e32834796e6.

6. Fletcher C, Unni K, Mertens F. Pathology and genetics of tumors of soft tissue and bone. In: ed. P. Kleihues World Health Organization Classification of Tumors. Lyon: International Agency for Research on Cancer Press; 2002.

7. Singer S, Antonescu CR, Riedel E, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003;238(3):358–370. DOI: 10.1097/01.sla.0000086542.11899.38.

8. Grasso E, Marino F, Bottalico M, et al. A case of myxoid liposarcoma of the retroperitoneum: a challenging tumour for diagnosis and treatment. Case Rep Surg 2014;2014: 572805. DOI: 10.1155/2014/572805.

________________________
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.